Insular Cortical Thickness in Patients With Somatoform Pain Disorder: Are There Associations With Symptom Severity and Childhood Trauma?

Elisabeth Meyer1*, Eva Morawa1, Yeliz Nacak1, Julie Rösch2, Arnd Doerfler2, Clemens Forster3† and Yesim Erim1†

Background: Studies show significant alterations in insular cortical thickness in patients with somatoform pain disorder (SPD). Additionally, associations between childhood maltreatment and morphometric alterations in insular cortex have been observed. Since patients with SPD often report about adverse childhood experiences, we were interested in the interrelationship of exposure to childhood maltreatment and insular cortical thickness in patients with SPD.

Methods: Fifteen adult patients with SPD (ICD-10 F 45.40/41, DSM-Code 307.80) and thirteen healthy adult controls underwent T1-weighted MR brain imaging. In the voxel-based morphometry (VBM) analysis we compared whole brain cortical thickness between patients and controls using a Student’s two-sampled t-test ($p < .05$). Then we performed a secondary analysis to detect differences in cortical thickness levels in the insular cortex between both groups. For further analysis of differences in insular cortical thickness we used gender, age, depressive symptoms [Patient Health Questionnaire (PHQ)-9], and whole brain cortical thickness as nuisance covariates. Subsequently we explored associations between insular cortical thickness, symptom severity (PHQ-15) and past experiences of childhood maltreatment (CTQ) in both groups.

Results: Patients showed reduced insular cortical thickness in a subregion of right Brodmann area (BA) 13 (anterior part of the insular cortex), whereas whole brain cortical thickness did not differ between groups. The between-group difference in the identified insular subregion of right BA 13 was not diminished by any of the covariates. This implies that the reduction in cortical thickness in the identified insular subregion might be due to a specific group effect. The effect sizes indicate that the group of patients experienced more childhood maltreatment than the control group. Nonetheless, significant correlations of insular cortical thickness with symptom severity and childhood maltreatment in the total collective could not be demonstrated for the group of patients.
INTRODUCTION

Patients with chronic somatoform pain disorder (SPD) suffer from pain which can not be explained by medical conditions thoroughly (1). Though the underlying mechanisms are not fully understood, a complex interaction of genetic predispositions, epigenetic influences, psychoneuroimmunological and social mechanisms is assumed to be involved in the development of somatoform pain [see (2)].

Previous research reported about differences in cortical thickness of various brain areas between patients with chronic pain disorders and controls (3–7). Although the pathophysiological impact of changes in cortical thickness is not clear yet, studies indicate that a reduction of gray matter is associated with degenerative mechanisms and impairments (8, 9). Several studies focused on changes in cortical thickness especially in the insular cortex in patients suffering from chronic pain (3, 7, 10). The insular cortex shares a wide variety of connections with other pain processing brain areas and in the anterior insula sensory input is liaised with cognitive, motivational, and emotional information from interconnected areas (see (11, 12)). Furthermore, Craig suggests that the anterior insula is involved in interoceptive processing and subjective feelings (13). Given its integrative accomplishment, the anterior insular cortex is said to sub-serve a state of emotional awareness and a condition of selfhood (13–15).

A reduction in gray matter volume - and thus in cortical thickness - might be attributed to overuse atrophy, secondary to excitotoxicity, or influence of inflammatory cytokines (see (16)). For example, in patients with major depressive disorder an elevated interleukin (IL)-6 serum level was associated with reduced prefrontal cortical thickness (17). Frodl et al. found that patients with major depressive disorder had a smaller hippocampal volume and showed higher plasma levels of IL-6 and C-reactive protein (CRP) than healthy controls (18). Animal models affirm that neuroinflammation has an effect on neuropathological mechanisms, including neurodegeneration (19) and decrease of neurogenesis (20, 21). Further, studies report about significantly elevated plasma and serum levels of proinflammatory cytokines like IL-6 and IL-8 (22) and elevated IL-8 levels in the cerebrospinal fluid (23, 24) in patients suffering from fibromyalgia. Elevated IL-8 levels in the cerebrospinal fluid were also found in patients with lumbar disc herniation (25), indicating that neuroinflammation plays a role in different forms of chronic pain disorders.

Other evidence suggests an association of early life stress like childhood trauma and pro-inflammatory states in adulthood (26). Early life stress itself comprises a variety of adverse conditions during childhood that are said to have effects on the adult’s mental constitution as well as the behavior, e.g., alcohol abuse or depression (27, 28). Childhood maltreatment is known to be an early life stressor and includes physical and/or emotional ill-treatment, sexual abuse, neglect, and other harmful conditions (29). Patients with somatoform pain disorder and fibromyalgia report about a higher frequency of experiences of maltreatment during childhood than controls with medically explained chronic pain (30). For example, around 32% of patients with somatoform pain disorder or fibromyalgia reported about frequent physical maltreatment during childhood compared to 11% in a control sample and sexual abuse was reported by 10–15% of the patients and 0% by the control group (30). Landa and colleagues suppose a shared physical and social pain neural system that implicates a higher susceptibility to somatoform pain as a result of adverse childhood experiences (2). Other studies consider alterations in cortical thickness as an anatomical correlate of childhood maltreatment (31–33) or a neural marker of increased risk for psychopathology (34). Normally, gray matter volume increases in the period of preadolescence and declines after adolescence, while white matter increases linearly (35). The underlying, well-regulated cellular maturational processes (36) might be disturbed by adverse childhood experiences and result in normative deviation in gray matter volume (see (37)). As delineated above, neuroimmunological processes might be one of the mediating factors between childhood maltreatment and changes in brain morphometry. Changes in gray matter volume which are associated with childhood maltreatment were mainly observed in the gyrus cinguli anterior, frontal and temporal areas, and in the insula (32–34, 38). Furthermore, gyriﬁcation deficits in the insular cortex seem to be associated with childhood maltreatment (34).

Since affective disorders and pain syndromes are often coincident, studies investigated the interaction of both on cortical thickness. While some findings point to vanishing differences in cortical thickness in pain syndromes when controlling for affective disorders (4), other studies surmise the concomitance of independent mechanisms (39). The thinning of cortical thickness itself could be associated with deficits in pain regulation and hence promote the manifestation of chronic pain. Alternatively, cortical thinning could be the consequence of

Conclusions: Our data suggest that alterations in the identified insular subregion of right BA 13 are associated with somatoform pain, independent of gender, age, or coincident depression levels. To identify significant associations of insular cortical thickness and experiences of childhood maltreatment in patients with SPD investigations within larger samples are highly recommended.

Keywords: somatoform pain, insula, cortical thickness, childhood maltreatment, voxel-based morphometry
continuous nociceptive input. Concerning the cross-sectional design of studies to the topic, both options are conceivable. Furthermore, a competing assumption points to possible increases in gray matter volume due to over-engagement of pain-modulatory functions (6).

Independent branches of research report about alterations in insular cortical thickness in patients with somatoform pain disorder as well as in people with a history of childhood maltreatment. Moreover, it is well established that patients with somatoform pain disorder often made the experience of childhood maltreatment. To our best knowledge, the interrelationship of these variables has not been addressed yet.

We hypothesize that patients diagnosed with somatoform pain disorder express differences in insular cortical thickness compared to healthy controls and that these differences correlate with higher symptom severity. Because studies showed an association between affective disorders and cortical thickness (40), we use depression as nuisance covariate. Furthermore, we postulate that these differences are associated with greater exposure to childhood maltreatment.

METHODS

Subjects
In the framework of an extensive investigation on somatoform pain disorders (see Nacak et al. (41) for detailed information) 65 patients suffering from somatoform pain disorder were compared with 65 age- and gender-matched healthy controls. Patients and controls were asked to participate in an additional MRI-session in case they were suitable (e.g., free of cardiac pacemaker). Overall 16 patients and 13 healthy controls participated in our MRI-exploration. Retrospectively one patient had to be excluded because of damaged MRI-data. At the time of data collection all patients met the criteria for “pain disorder associated with psychological factors” [International Classification of Diseases (ICD)-10 F 45.40/41 (42) or DSM-Code 307.80 (43)]. Thus, the patients sample included persons suffering from chronic pain of any kind (e.g., back pain, headache, fibromyalgia) accompanied by psychological distress and impairments in several functions. In order to verify the patients’ diagnoses, the survey made use of the Structured Clinical Interview (SCID-I) for Axis-I-disorders (44). The subsampled control group consisted of 13 healthy persons who were matched for age and gender. Using the short-version of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV it was reassured that they did not meet the criteria for somatization or mental disorders. All participants were asked to complete the questionnaires described below before neuroimaging.

Exclusion criteria for both participants and control group involved current alcohol or substance abuse, relevant organic disorders or medical preconditions, mental disorders with psychotic symptoms, and language barriers. Additionally, participants younger than 18 years and older than 65 years were excluded from the study.

Informed consent was obtained from all participants and the study was approved by the local ethic committee of the Friedrich-Alexander Universität Erlangen-Nürnberg (approval number: 46_14B).

Neuroimaging

Image Acquisition
High-resolution three-dimensional images were acquired using a 3 T Siemens MAGNETOM Trio Tim scanner (Siemens, Erlangen) with the software version syngo MR B17. For the anatomical scans, a T1-weighted sequence with transversal slices and a 12-channel triple mode head coil was used (176 slices per slab; slice thickness = 1 mm; resolution 1 mm³; TE = 2.52 ms; TR = 1.900 ms; FA = 9; FoV = 256 mm; FoV phase = 100%; phase resolution = 100%). Images were analyzed with BrainVoyager3.2 (Brain Innovation B.V., Maastricht, the Netherlands; www.brainvoyager.com).

Voxel-Based Morphometry Analysis
To make the original data suitable for advanced segmentation, raw data was up-sampled to a 0.5 mm resolution using sinc interpolation. Preparatory steps for cortical thickness measurement were performed using a segmentation tool that separated the cortex from surrounding structures like the cerebellum and subcortical structures and estimated the WM-GM (white and gray matter) and GM-CSF (gray matter and cerebrospinal fluid) boundaries as precisely as possible. These different classes of brain tissues are identified based on the intensity of the signal of each voxel. The according thresholds were adaptively calculated by inspecting local intensity histograms as well as computed gradient fields (for details see (45)).

For the measurement of cortical thickness, the Laplace method as introduced by Jones (46) was used. This method finds the cortical thickness at a certain voxel solving a partial differential equation such that the optimum spatial direction representing the local thickness is found. This is done in a repeated manner from starting at a source voxel (e.g., one at the GM-CSF boundary) and continuing along a transition of intensities. With this, for every GM voxel gradient vectors were computed. The gradient was first followed in one direction and then in the opposite direction. The integrated values of the accumulated step sizes until a boundary voxel was reached resulted in a pathlength. The pathlengths from the two directions were finally added to obtain the thickness measure for the GM voxel.

Each participants’ data was transformed into individual volume maps (IVMs). IVMs represent information of the individuals’ cortical thickness in a voxel-wise level. The whole brain cortical thickness was calculated as the sum of each IVM. With this the whole brain cortical thickness of the patients’ IVMs were compared with that of the control group using a Student’s two-sampled t-test (p < .05).

In respect of our a priori interest a secondary analysis was performed to highlight differences in cortical thickness levels in the insular cortex between patients and the control group. The respective anatomical localization was determined using the application "MNI/Talairach with Brodmann areas (1.09)" of the Yale BioImage Suite Package (47).
A secondary analysis compared the IVMs between the groups on a voxel-based level and highlights brain areas that significantly differ in cortical thickness. A difference in cortical thickness of a certain brain area between the groups was considered if it consists of at least 200 contiguous significant voxels (25 mm³).

**Psychometrics**

**Patient Health Questionnaire (PHQ-15, PHQ-9)**

To assess the severity of somatic symptoms, the Patient Health Questionnaire (PHQ)-15 module of the German PHQ was used (48). The module includes 15 self-report-items, which conform to the symptoms of DSM-IV somatization disorder. The total PHQ-15 score ranges from 0 to 30 points. Depressive symptoms in patients and controls were evaluated with the PHQ-9 module of the German PHQ (48). A total of nine self-report items coincide with the DSM-IV Diagnostic Criteria for Major depression disorder. The total PHQ-9 score ranges from 0 to 27 points. Both PHQ-15 and PHQ-9 scores represent mild symptoms from 5 to 9 points, moderate symptoms from 10 to 14 points, and severe symptoms from 15 to 30 (respectively 27) points. German PHQ-15 and PHQ-9 show good psychometric properties (49–51).

**Childhood Trauma Questionnaire**

Experiences of childhood maltreatment were enquired with the 28-item short form of the Childhood Trauma Questionnaire (CTQ) (52) in German language (53). Subscale scores represent the severity of five types of traumatic experiences (physical-, sexual-, and emotional abuse and physical and emotional neglect) and range from 5 (no abuse or neglect) to 25 (maximum of abuse or neglect). Furthermore, a total score from 25 to 125 depicts the gravity of overall maltreatment. The evaluation strategy was based on Wingenfeld and colleagues (54). Three items, which neither contribute to these five subscales nor to the total CTQ score, contribute to the additional subscale minimization/denial. This subscale measures the tendency to trivialize memories (subscale score ranges from 0 to 3 points). The CTQ in German language has good psychometric properties, except for a low internal consistency of the subscale physical neglect (53, 54).

**Statistics**

Statistical analyses were conducted with BrainVoyager3.2 and SPSS 25.0 (SPSS Inc., Chicago, Illinois). Descriptive characteristics are represented as mean values, standard deviations, ranges, and frequencies. Sociodemographic and clinical characteristics of the subjects were evaluated with two-sampled t-tests and χ²-tests in SPSS (if our data did not fulfill statistical assumptions, we calculated Mann-Whitney-U-tests and Fisher’s exact test instead). PHQ-15 and PHQ-9 were completed by each participant, while CTQ was not filled out by one patient and two healthy controls (i.e., 14/15 and 11/13). Student’s two-sampled t-test provided by BrainVoyager3.2 was used to identify differences in whole brain cortical thickness between groups (p < .05). In the subsequent secondary analysis we used Student’s two-sampled t-test to detect subregions in the insular cortex, which showed differences in cortical thickness between patients and healthy controls. These tests are run on a voxel-wise level. For a further statistical analysis we extracted the value of whole brain cortical thickness and the cortical-thickness-values of these identified insular subregions of each participant from BrainVoyager to SPSS. These values were used to calculate the relationship between cortical thickness in the identified insular subregions and somatoform pain disorder while controlling for the level of depression (PHQ-9) and other covariates. For this purpose we performed an analysis of covariance (ANCOVA) with two independent groups and two fixed factors (group and gender). In addition to PHQ-9 scores (i.e., level of depression) we used whole brain cortical thickness and age as additional nuisance covariates, because both parameters are also known to have an influence on cortical thickness. Because ANCOVA is considered to be robust against violations of assumptions rather well, we did not use alternative statistical methods. In a subsequent step we calculated Pearson correlation coefficients of cortical thickness in the identified insular subregions with age, somatic symptom severity (PHQ-15), level of depression (PHQ-9), and experiences of childhood maltreatment (CTQ total and subscale scores). If the assumption of normality was not fulfilled, we calculated Spearman correlation coefficients. The effect size was measured with Cohens’ d (55) and r². An online tool was used to calculate Cohen’s d and confidence intervals (56). For all analyses the level of significance was predetermined at p ≤ .05.

**RESULTS**

**Subjects’ Sociodemographic and Clinical Characteristics**

For detailed information about the sociodemographic characteristics of our participants, see Table 1. Since our sample was age- and gender-matched, patients and healthy controls did not differ by age or distribution of gender. While the control-group was free of chronic pain, patients reported an average pain duration of 10.7 years (SD = 8.8 years). There was no significant difference in pain duration between female and male patients. As delineated above, different types of chronic pain were reported by the group of patients (see Table 1). It has to be noted, that some patients even named more than one type of chronic pain (e.g., migraine and fibromyalgia), while other patients did not specify the kind of chronic pain they suffer from. The use of antidepressants and pain medication was only prevalent in the patient group. Table 2 shows the clinical characteristics of patients and controls. The mean score of somatic symptom severity (PHQ-15) and the degree of depressive symptoms (PHQ-9) was significantly higher in patients compared to healthy controls. The effect sizes referring to the total CTQ-score and the CTQ-subscases indicate that experiences of childhood maltreatment were more occurrent in the group of patients than in the control group.

**Voxel-Based Morphometry-Analysis**

Though patients tend to a smaller whole brain cortical thickness than the control group, the difference was not significant (see
Table 2 and Figure 1A). Since it is known that cortical thickness undergoes a thinning process, we calculated the correlation between whole brain cortical thickness and age. While there was a slightly significant correlation in the control group between whole brain cortical thickness and age ($r = -0.55$, $p = 0.051$), patients showed no significant association between both parameters ($r = -0.46$, $p = 0.084$). With Student’s two-sampled t-tests in BrainVoyager we could identify one single significant subregion in the insular cortex, which is located in right Brodmann area 13 ($X = -36; Y = -8; Z = -4$). This subregion is part of the anterior insular cortex and is formed by 225 voxels. As it can be seen in Figure 1B, it represents a significant reduction parameters ($r = -0.46$, $p = 0.084$). With Student’s two-sampled t-tests in BrainVoyager we could identify one single significant subregion in the insular cortex, which is located in right Brodmann area 13 ($X = -36; Y = -8; Z = -4$). This subregion is part of the anterior insular cortex and is formed by 225 voxels. As it can be seen in Figure 1B, it represents a significant reduction

**TABLE 1 | Demographic characteristics of patients and healthy controls.**

| Variables                              | Patients ($n = 15$) | Controls ($n = 13$) | U Score/ $\chi^2$ | $p$  |
|----------------------------------------|---------------------|---------------------|------------------|-----|
| Age                                    | 49.1 ± 11.0 (25–61) | 43.0 ± 12.2 (25–61) | 61.50            | .098a|
| Gender, n (%)                          | 11 (73.3%)          | 9 (69.2%)           | .06             | .99b |
| Partnership status, n (%)             | 5 (33.3%)           | 7 (53.8%)           | .27c            |     |
| Educational level, n (%)              | 12 (80.0%)          | 6 (46.2%)           | .11d            |     |
| Pain duration, years, Mean ± SD       | 10.7 ± 8.8          | -                   | -               | -   |
| Employment status, n (%)              | 9 (60.0%)           | 11 (84.6%)          | .22e            |     |
| Use of antidepressants, n (%)         | 11 (73.3%)          | -                   | -               | -   |
| Use of pain medication, n (%)         | 9 (60.0%)           | -                   | -               | -   |

*aMann-Whitney-U-test, two-tailed; bFisher’s exact test, two-tailed; cFisher’s exact test, two-tailed; dmultiple mentions possible.

**TABLE 2 | Clinical characteristics of patients and healthy controls.**

| Variable                          | Patients ($n = 15$) | Controls ($n = 13$) | T Score/U score | $p$  | Cohen’s $d$ (95% CI) |
|-----------------------------------|---------------------|---------------------|----------------|-----|---------------------|
| PHQ-15, mean ± SD (range)         | 13.20 ± 4.65 (5–20) | 2.06 ± 1.85 (0–7)   | 1.50           | .001b| -3.06 (−4.15; −1.97)|
| PHQ-9, mean ± SD (range)          | 13.07 ± 5.31 (5–24) | 2.06 ± 1.85 (0–6)   | 2.00           | .001b| -2.66 (−3.71; −1.66)|
| CTQ total score, mean ± SD (range) | 40.57 ± 21.10 (25–89) | 35.82 ± 9.05 (26–50) | 2.04           | .056 | -0.75 (−1.57; 0.06) |
| Sexual abuse, mean ± SD (range)   | 6.86 ± 4.52 (6–18)  | 5.56 ± 1.29 (9–17)  | 73.50          | .85  | −0.37 (−1.17; 0.42) |
| Physical abuse, mean ± SD (range) | 8.29 ± 5.03 (5–20)  | 6.18 ± 2.04 (9–17)  | 71.00          | .40  | −0.53 (−1.33; 0.28) |
| Emotional abuse, mean ± SD (range) | 9.43 ± 4.55 (6–19)  | 6.64 ± 1.86 (5–10)  | 48.00          | .12  | −0.77 (−1.59; 0.05) |
| Minimization, mean ± SD (range)   | 10.93 ± 6.37 (5–25) | 7.64 ± 2.69 (5–12)  | 57.50          | .29  | −0.64 (−1.45; 0.17) |
| Whole brain cortical thickness (ml) | 628.15 ± 35.05 (580.29–706.24) | 636.12 ± 39.65 (574.06–705.69) | -0.57         | .58  | 0.21 (−0.53; 0.96)  |

*aStudent’s t test, two-tailed; bMann-Whitney-U-test, two-tailed; CTQ, Childhood Trauma Questionnaire; GMV, gray matter volume. Significant T scores/U scores and $p$-values are marked in bold. cThe CTQ was only completed by 14 patients and 11 healthy controls. dCI, confidence interval.
in cortical thickness in the patient group compared to healthy controls [on a voxel-wise level: t (26) = −2.94, p = .009]. In this subregion patients showed a mean cortical thickness of 2.27 mm (SD = 1.21 mm; min = 0.31 mm; max = 4.26 mm), whereas healthy controls showed a mean cortical thickness of 4.25 mm (SD = 1.47 mm; min = 1.89 mm; max = 6.98 mm). Just like the whole brain cortical thickness, the cortical thickness in the identified insular subregion is independent of age for both patients (r = −.05, p = .85) and healthy controls (r = −.13, p = .66). In a subsequent analysis we compared the mean cortical thickness of the identified insular subregion between groups while using age, whole brain cortical thickness, and depressive symptoms as nuisance covariates. Group and gender were used as fixed factors. In Table 3, it is illustrated that the primary between-group effect remained significant.

**Association of Insular Cortical Thickness With Somatic Symptoms and Traumatic Childhood Experiences**

Correlation coefficients between cortical thickness in the identified insular subregion with age, level of depression (PHQ-9), somatic symptoms (PHQ-15), and traumatic childhood experiences (CTQ) are presented in Table 4 for the entire sample and in the right column for the group of patients. Negative coefficients represent more somatic symptoms and more traumatic experiences in the patient group compared to healthy controls [on a voxel-wise level: t (26) = −2.94, p = .009]. In this subregion patients showed a mean cortical thickness of 2.27 mm (SD = 1.21 mm; min = 0.31 mm; max = 4.26 mm), whereas healthy controls showed a mean cortical thickness of 4.25 mm (SD = 1.47 mm; min = 1.89 mm; max = 6.98 mm). Just like the whole brain cortical thickness, the cortical thickness in the identified insular subregion is independent of age for both patients (r = −.05, p = .85) and healthy controls (r = −.13, p = .66). In a subsequent analysis we compared the mean cortical thickness of the identified insular subregion between groups while using age, whole brain cortical thickness, and depressive symptoms as nuisance covariates. Group and gender were used as fixed factors. In Table 3, it is illustrated that the primary between-group effect remained significant.

**TABLE 3 | Differences in cortical thickness in the identified insular subregion in Brodmann area (BA) 13 between patients with somatoform pain disorder and healthy controls (whole brain cortical thickness, age, and depression as nuisance covariates).**

| Source                  | Mean of squares | F     | p     | η²  |
|-------------------------|-----------------|-------|-------|-----|
| Group effect            | 9.68            | 4.97  | .037  | .19 |
| Gender                  | 2.95            | 1.51  | .23   | .07 |
| Group effect x gender   | 0.69            | 0.35  | .56   | .02 |
| Whole brain cortical thickness | 0.61 | 0.32  | .58   | .02 |
| Age                     | 0.84            | 0.43  | .52   | .02 |
| Depressive symptoms (PHQ-9) | 0.86 | 0.44  | .52   | .02 |

PHQ, Patient Health Questionnaire; F, F score of the analysis of covariance (ANCOVA). Significant p-values are marked in bold.

**TABLE 4 | Correlation-coefficients of cortical thickness in the identified insular subregion in Brodmann area (BA) 13 (X = 36; Y = −8; Z = −4) with somatic symptoms severity and traumatic childhood experiences.**

| Source                  | Whole sample n = 28 | Patients n = 15 |
|-------------------------|---------------------|-----------------|
|                        | r       | p        | r       | p      |
| Age                    | −.31b   | .11      | −.06b   | .85    |
| PHQ-15                 | −.65b   | <.001    | −.39b   | .15    |
| PHQ-9                  | −.50b   | .007     | −.17b   | .32    |
| CTQ total score        | −.26b   | .21      | −.10b   | .73    |
| CTQ physical abuse     | −.38b   | .064     | −.32b   | .27    |
| CTQ emotional abuse    | −.15b   | .47      | −.06b   | .83    |
| CTQ sexual abuse       | .07b    | .73      | −.00b   | .99    |
| CTQ physical neglect   | −.45b   | .023     | −.27b   | .35    |
| CTQ emotional neglect  | −.20a   | .34      | −.10a   | .72    |
| CTQ minimization/denial | −.25b   | .24      | −.52b   | .060   |

aPearson’s r, two-tailed; bSpearman ρ, two-tailed; PHQ, Patient Health Questionnaire; CTQ, Childhood Trauma Questionnaire. Significant correlation-coefficients and p-values are marked in bold.
childhood experiences in persons with less cortical thickness in the identified insular subregion. The relationship between cortical thickness in the identified insular subregion in right Brodmann area (BA) 13 and symptom severity (PHQ-15), CTQ total score and CTQ subscale physical neglect is visualized in Figures 2A–C.

DISCUSSION

The aim of the study was to investigate whether insular cortical thickness differs between patients with somatoform pain disorder and healthy controls. Using voxel-based morphometry we identified a local reduction in cortical thickness in the anterior insular cortex in patients, though the whole brain cortical thickness was the same in both groups. Furthermore, we were interested in associations between insular cortical thickness, symptom severity, and experiences of childhood maltreatment. Whereas significant correlations between insular cortical thickness, symptom severity, and childhood maltreatment were observed in the total collective, associations in the group of patients missed significance.

Insular Cortex

Previous research on insular cortical thickness alterations in pain disorders have shown ambiguous results. Most studies report about a decline in insular cortical thickness and other pain areas in chronic pain syndromes (3, 7, 10). In contrast, Ceko showed an age-dependent increase in insular cortical thickness in younger patients with fibromyalgia (6). The authors surmised the increment in cortical thickness to reflect an adaptive coping mechanism, which exhausts with increasing age. They suggest that this process results in a reduction of insular gray matter volume only present in older patients, but not in younger patients or healthy controls. Furthermore, the influence of affective disorders on cortical thickness and possible interactions with chronic pain have been discussed controversially (4, 7, 39). With this investigation, we intended to evaluate the mere relation of somatoform pain and insular cortical thickness, independent of age, and depressive symptoms. For this purpose, we tried to eliminate the influence of age and depression by treating them as nuisance covariates. Our data indicate that insular cortical thickness is reduced in patients compared to healthy controls, independent of effects of age or depression.

Age

We found that whole brain cortical thickness, which does not differ between groups, is not associated with age. The same accounts for the identified insular subregion in BA 13. The observation, that insular gray matter volume is age-dependent in patients with fibromyalgia (6), could not be confirmed in our sample, neither for patients nor for healthy controls. Though missing significance, the correlation of whole brain cortical thickness with age was considerably higher compared to the correlation of cortical thickness in the identified insular subregion. This could render a hint that insular cortical thickness might be more dependent on other sources of influence than on aging mechanisms, whereas other brain regions are more prone to senescence.

Depressive Symptoms

Patients reported significantly more depressive symptoms than healthy controls. Because the influence of affective disorders on brain morphometry is well known, we entered depression in our analysis as a covariate. When Hsu and colleagues controlled for affective disorders, differences in insular gray matter volume between patients with fibromyalgia and healthy controls diminished (4). We tried to question this by using depressive symptoms as additional nuisance covariate and found that the group effect remained significant. This finding supports other surveys which assume that both pain and affective disorders exert influence on insular morphometry, but each with individual and differing mechanisms. So far, the significant correlation of cortical thickness in the identified insular subregion with depressive symptoms in the total collective affirms the recommendation to consider level of depression in investigations about cortical thickness.

Symptom Severity

Patients showed a significantly higher symptom severity than controls. This observation is not surprising given that the control group does not conform to the clinical diagnosis of chronic pain disorder. Nonetheless, occasional experiences of pain were reported by healthy controls as well (see PHQ-15 score in Table 2). We observed a strong negative association between symptom severity and cortical thickness in the identified insular subregion in the total collective (i.e., cortical thinning in this subregion correlates with higher symptom severity). Referring to the outstanding role of the anterior insular cortex in pain processing, we assume that the ability to deal with pain deteriorates with decreasing cortical thickness in the anterior insular cortex. If the gray matter volume in the anterior insular cortex falls below a critical value, the anterior insular cortex might lose essential abilities in pain processing mechanisms which results in a condition of chronic pain. There is also a negative association between symptom severity and cortical thickness in the identified insular subregion in the patient group, but the correlation missed significance. Maybe this relation should be verified within a larger sample. Alternatively, the reason why we failed to proof an association could be due to the gender characteristics of our sample. In contrast to our gender-mixed sample, most data about fibromyalgia and somatoform pain were collected within all-female samples. This is relevant to the topic, because females are said to report more physical symptoms than men (57, 58). One possible explanation might be that a higher “attentiveness to altered body states” inheres in women (59). Concerning that, the rate of symptom severity and consequently the correlation of cortical thickness and symptom severity might be underestimated in our survey compared to studies with exclusively female patients.

Childhood Maltreatment and Insular Cortical Thickness

A central question of this investigation refers to associations between experiences of childhood maltreatment and changes in insular cortical thickness in patients with somatoform pain disorder. As
delineated above, patients with pain syndromes often faced traumatic experiences during childhood or adulthood (30, 60, 61). Presumably mediated by intensified neuroinflammatory processes, changes in brain morphometry might be promoted. In turn, alterations in brain morphometry like reduced cortical thickness in specific brain processing areas might increase the vulnerability to the development of somatoform pain disorders. It has to be noted that previous research focused mainly on prefrontal and temporal regions, as well as the gyrus cinguli anterior. Until now the association between insular cortex morphometry and adverse childhood experiences has been examined in very few investigations (33, 34). Referring to the medium-to-large effect sizes our data support the assumption that patients with somatoform pain disorder were more often exposed to childhood maltreatment than the comparative group of healthy persons. Only for two subscales (sexual abuse and minimization) the effects were low. To increase the statistical power and the validity of results it is highly recommended that further research should be undertaken in larger samples. Besides to that we assume the way we assessed childhood maltreatment might be not sufficient to the question. Commonly, one main problem in asking adults about experiences of childhood maltreatment is the assessment in retrospect. Especially false negative reports are frequent recall problems (62) and the current psychic and mental status can influence memory processing and fuel recall biases (see (63)). To heighten the accuracy of retrospective reports about childhood experiences, future research could use biographic interviews, interviews of siblings, or similar in addition to questionnaires.

Furthermore, we were interested in possible associations between cortical thickness in the identified insular subregion and exposure to childhood maltreatment. The results of our investigation could not strengthen the assumption about a negative association of cortical thickness in the identified insular subregion and the experience of childhood maltreatment, except for the subscale physical neglect: In the total collective we found a significant negative correlation between physical neglect and cortical thickness in the identified insular subregion in BA 13. This result implies that people with a greater experience of physical neglect during childhood might show a decline in cortical thickness in the anterior part of the insula. As the anterior insular cortex is said to provide services of interoception and a state of self-awareness (see (13)), we suggest that a deficit of physical stimulation might reduce the informational input for the anterior insular cortex in a sensitive developmental period. That might result in reduced local gray matter volume and maybe subsequently compromise the ability to deal with experiences of pain. This assumed interrelation might play a critical role in the multifactorial developmental mechanisms of chronic pain disorders. Nonetheless it has to be considered, that the internal consistency of the subscale physical neglect is rather weak (53) and that we could not confirm associations of physical neglect and cortical thickness in the identified insular subregion for the group of patients. Since only 14 patients completed the questionnaire about childhood maltreatment, it would be expedient to repeat our investigation within a larger sample.

**Strengths and Limitations**

Our study targets on linking insular cortex morphometry with childhood maltreatment in patients suffering from somatoform pain disorder. To our best knowledge, this is the first time that this specific interrelation is explored. One strength of our study is the accurate matching of patients and healthy controls for age and gender. Although we did not match our samples for further characteristics, there were no significant differences in educational level, partnership or employment status between groups (see Table 1). Furthermore, we tried to minimize the impact of factors which are known to affect cortical thickness themselves. That’s why we included gender, whole brain cortical thickness, age, and depressive symptoms in our exploration. Hence, the reduction in cortical thickness in the identified insular subregion in BA 13 in patients with somatoform pain disorder most probably represents a specific group effect. Notwithstanding the generalization of our results is limited by some factors. First, the main weakness of our study is the relatively small sample size and therefore low statistical power. Second, most data about fibromyalgia and somatoform pain was collected within mere female samples. As women report more physical and somatoform symptoms compared to men (57, 58), our results might be rarely comparable with other investigations. Nonetheless we assume investigations with mixed samples to be reasonable, because somatoform pain disorders affect both women and men. Another limiting factor is that we did not consider a systematic influence of medication usage on our analyses. Although we asked the participants to pause pain medication and intake of antidepressants for 24 h prior to the MRI-session, we cannot estimate the influence of prolonged effects of the medication on brain imaging. Since pain medication intake and usage of antidepressants are assumed to affect gray matter volume (64, 65), it might be possible that our results are associated with medication-related effects. Another limitation of our exploration is the way how childhood maltreatment was assessed. As explained above, retrospective evaluations are often superimposed with falsification. Hence, it is difficult to rate the accuracy of the reports. Finally, the major limitation of our study is up to its cross-sectional design. We need prospective research to review the causal direction and complex relation of changes in cortical thickness, childhood maltreatment and somatoform pain disorder.

**Implications for Future Research**

Taking into account current findings about the role of proinflammatory cytokines in developmental and maintaining processes of chronic pain, it would be interesting to put relevant markers in serum and/or cerebrospinal fluid in relation to neuroanatomical characteristics and experiences of childhood maltreatment in the target group. Considering and examining as many relevant factors in the etiology of somatoform pain disorder as possible in future research will help to establish appropriate diagnostic and therapeutic tools for patients affected.

**AUTHOR’S NOTE**

The present work was performed in fulfillment of the requirements for obtaining the degree “Dr. med.” for author Elisabeth Meyer.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Local ethic committee of the Friedrich-Alexander Universität Erlangen-Nürnberg (approval number: 46_14B). The approved by Local ethic committee of the Friedrich-Alexander

REFERENCES
1. ICD-10-GM. Systematic list. International Statistical Classification of Diseases and Related Health Problems, 10th revision. German Modification -. Köln: DIMDI (2019).
2. Land a, Peterson BS, Fallon BA. Somatoform pain: a developmental theory and translational research review. Psychosom Med (2012) 74(7):717–27. doi: 10.1097/PSY.0b013e3182886860
3. Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chiaib BA, Bushnell MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci (2007) 27(15):4004–7. doi: 10.1523/JNEUROSCI.0098-07.2007
4. Hsu MC, Harris RE, Sundgren PC, Welsh RC, Fernandes CR, Clawd DJ, et al. No consistent difference in gray matter volume between individuals with fibromyalgia and age-matched healthy subjects when controlling for affective disorder. Pain (2009) 143(3):262–7. doi: 10.1016/j.pain.2009.03.017
5. Diaz-Piedra C, Guzman MA, Buela-Casal G, Catena A. The impact of fibromyalgia symptoms on brain morphology. Brain Imaging Behav (2016) 10(4):1184–97. doi: 10.1007/s11682-015-9485-2
6. Ceko M, Bushnell MC, Fitzcharles MA, Schweinhardt P. Fibromyalgia interacts with age to change the brain. NeuroImage Clin (2013) 3:249–60. doi: 10.1016/j.nicl.2013.08.015
7. Valet M, Gündel H, Sprenger T, Sorg C, Mühlau M, Zimmer C, et al. Patients with pain disorder show gray-matter loss in pain-processing structures: a voxel-based morphometric study. Psychosom Med (2009) 71(1):49–56. doi: 10.1097/PSY.0b013e318181d1e2
8. Li M, Meng Y, Wang M, Yang S, Wu H, Zhao B, et al. Cerebral gray matter volume reduction in subcortical vascular mild cognitive impairment patients and subcortical vascular dementia patients, and its relation with cognitive deficits. Brain Behav (2017) 7(8):e00745. doi: 10.1002/brb3.745
9. Ray NJ, Bradburn S, Murgatroyd C, Toseeb U, Mir P, Kountouriotis G, et al. Novel cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson’s disease. Brain J Neurol (2018) 141(1):165–76. doi: 10.1093/brainawx310
10. Robinson ME, Cragns JG, Price DD, Perlstein WM, Staud R. Gray matter volumes of pain-related brain areas are decreased in fibromyalgia syndrome. J Pain (2011) 12(4):436–43. doi: 10.1016/j.jpain.2010.10.003
11. Morton DL, Sandhu JS, Jones AK. Brain imaging of pain: state of the art. Frontiers in Psychiatry | www.frontiersin.org September 2020 | Volume 11 | Article 4971009
12. Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chiaib BA, Bushnell MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci (2007) 27(15):4004–7. doi: 10.1523/JNEUROSCI.0098-07.2007
13. Valet M, Gündel H, Sprenger T, Sorg C, Mühlau M, Zimmer C, et al. Patients with pain disorder show gray-matter loss in pain-processing structures: a voxel-based morphometric study. Psychosom Med (2009) 71(1):49–56. doi: 10.1097/PSY.0b013e318181d1e2
14. Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chiaib BA, Bushnell MC. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci (2007) 27(15):4004–7. doi: 10.1523/JNEUROSCI.0098-07.2007
15. Seth AK. Interoceptive inference, emotion, and the embodied self. Trends Cognit Sci (2013) 17(11):565–73. doi: 10.1016/j.tics.2013.09.007
16. Mattson MP. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuronmol Med (2003) 3(2):65–94. doi: 10.1385/mm:3:2:65
17. Kakeda S, Watanabe K, Katsuki A, Sugimoto K, Igata N, Ueda I, et al. Relationship between interleukin (IL)-6 and brain morphology in drug-naïve, first-episode major depressive disorder using surface-based morphometry. Sci Rep (2018) 8(1):10054. doi: 10.1038/s41598-018-28300-5
18. Frodl T, Carballido A, Hughes MM, Salek K, Fagan A, Skokauskas N, et al. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry (2012) 2(3):e88. doi: 10.1038/tp.2012.14
19. Campbell IL, Abraham CR, Mislash E, Kemper P, Ingalls JD, Oldstone MB, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U.S.A. (1993) 90(21):10061–5. doi: 10.1073/pnas.90.21.10061
20. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science (2003) 302(5651):1765–6. doi: 10.1126/science.1088417
21. Vallières L, Campbell IL, Gage FH, Sawchenko PE. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci (2002) 22(2):486–92. doi: 10.1523/NEUROSCI.22-02-00486.2002
22. Üçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord (2011) 12:245. doi: 10.1186/1471-2474-12-245
23. Bäckryd E, Tanum L, Lind AL, Larsson A, Gordh T. Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. J Pain Res (2017) 10:315–25. doi: 10.2147/jpr.s128508
24. Kadetof D, Lampa J, Westman M, Andersson M, Kosek E. Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroinflammation (2012) 242(2):33–8. doi: 10.1246/jnri.2011.01.103
25. Palada V, Ahmed MS, Finn A, Berg S, Svensson CI, Kosek E. Characterization of neuroinflammation and periphery-to-CNS inflammatory cross-talk in patients with disc herniation and degenerative disc disease. Brain Behav Immun (2019) 75:60–71. doi: 10.1016/bbi.2018.09.010
26. Baumeister D, Akhtar R, Ciufolini S, Pariente CM, Mondelli V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. Mol Psychiatry (2016) 21(3):642–9. doi: 10.1038/mp.2015.67
27. Danese A, Moffitt TE, Harrington H, Milne BJ, Polanczyk G, Pariente CM, et al. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Arch Pediatr Adolesc Med (2009) 163(12):1133–43. doi: 10.1001/archpediatrics.2009.214
28. Enoch MA. The role of early life stress as a predictor for alcohol and drug dependence. Psychopharmacol (Berl) (2011) 214(1):171–31. doi: 10.1007/s00213-010-1916-6
29. WHO. Child maltreatment. Available at: https://www.who.int/news-room/factsheets/detail/child-maltreatment (Accessed August 4, 2020).
30. Imbierowicz K, Egle UT. Childhood adversities in patients with fibromyalgia and somatoform pain disorder. Eur J Pain (2003) 7(2):113–9. doi: 10.1016/s1090-3801(02)00721-1

AUTHOR CONTRIBUTIONS
YE and YN designed the study. AD and JR provided the MRI data. CF instructed ELM during the preparation and evaluation process of the MR images. EvM supported ELM and finalizing the manuscript.
31. Gold AL, Sheridan MA, Peverill M, Busso DS, Lambert HK, Alves S, et al. Childhood abuse and reduced cortical thickness in brain regions involved in emotional processing. *J Child Psychol Psychiatry* (2016) 57(10):1154–64. doi: 10.1111/jcpp.12630

32. Tomoda A, Suzuki H, Rabi K, Sheu YS, Polcari A, Teicher MH. Reduced prefrontal cortical gray matter volume in young adults exposed to harsh corporal punishment. *Neuroimage* (2009) 47(Suppl 2):T66–71. doi: 10.1016/j.neuroimage.2009.03.005

33. Edmiston EE, Wang F, Mazure CM, Guiney J, Sinha R, Mayes LC, et al. Corticostriatal-limbic gray matter morphology in adolescents with self-reported exposure to childhood maltreatment. *Arch Pediatr Adolesc Med* (2011) 165(12):1069–77. doi: 10.1001/archpediatrics.2011.565

34. Kelly PA, Viding E, Wallace GL, Scher A, De Brito SA, Robustelli B, et al. Cortical thickness, surface area, and gyration abnormalities in children exposed to maltreatment: neural markers of vulnerability? *Biol Psychiatry* (2013) 74(11):845–52. doi: 10.1016/j.biopsycho.2013.06.020

35. Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, et al. Brain development during childhood and adolescence: a longitudinal MRI study. *Nat Neurosci* (1999) 2(10):861–3. doi: 10.1038/13158

36. Sowell ER, Thompson PM, Toga AW. Mapping continued brain growth and gray matter density reduction in dorsal frontal cortex: Inverse relationships during postadolescent brain maturation. *J Neurosci* (2001) 21(22):8819–29. doi: 10.1523/JNEUROSCI.21-22-08819.2001

37. Hart H, Rubia K. Neuroimaging of child abuse: a critical review. *Front Hum Neurosci* (2012) 6:52. doi: 10.3389/fnhum.2012.00052

38. De Brito SA, Viding E, Sebastian CL, Kelly PA, Mechelli A, Maris H, et al. Reduced orbitofrontal and temporal gray matter in a community sample of maltreated children. *J Child Psychol Psychiatry* (2013) 54(1):105–12. doi: 10.1111/j.1469-7610.2012.02597.x

39. Jensen KB, Srinivasan P, Spaeth R, Tan Y, Kosek E, Petzke F, et al. Childhood abuse and reduced cortical thickness and brain volume in offenders. *Front Hum Brain Mapp* (2018) 8:1497. doi: 10.3389/fnhum.2018.01497

40. Suh JS, Schneider MA, Minuzzi L, MacQueen GM, Strother SC, Kennedy SH, et al. Childhood maltreatment and brain development: Inverse relationships during postadolescent brain maturation. *Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci* (1999) 2(10):861–3. doi: 10.1038/13158

41. Jones SE, Buchbinder BR, Aharon I. Three-dimensional mapping of cortical thickness using Laplace’s equation. *Hum Brain Mapp* (2000) 11(1):12–32. doi: 10.1002/1097-0193(200009)11:1<1::AID-hbm20>3.0.co;2-k

42. APA. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Press: Washington DC (2000).

43. Wittchen HU, Zaudig M, Fydrich T. *SCID I: Structured Clinical Interview for DSM-IV Axis I: Mental Disorder*. Hogrefe: Göttingen, German (1997).

44. Goebel R. (2014). Available at: http://www.brainvoyager.com/bvq/doc/UsersGuide/Segmentation/AdvancedSegmentationTools.html (Accessed May 16, 2019).

45. Jones SE, Buchbinder BR, Aharon I. Three-dimensional mapping of cortical thickness using Laplace’s equation. *Hum Brain Mapp* (2000) 11(1):12–32. doi: 10.1002/1097-0193(200009)11:1<1::AID-hbm20>3.0.co;2-k

46. Available at: http://sprout022.sprout.yale.edu/mini2tal/local2tal.html (Accessed May 16, 2019).

47. Löwe B, Spitzer RL, Zipfel S, Herzog W. [Patient Health Questionnaire (PHQ-D). Complete version and short version. 2nd edition]. Pfister: Karsruhe, Germany (2002).

48. APA. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Press: Washington DC (2000).

49. Kocalevent RD, Hinz A, Brähler E. Standardization of a screening instrument for somatoform disorder: the patient health questionnaire (PHQ-9). *Psychiatry Res Neuroimaging* (2018) 1281:35–42. doi: 10.1016/j.pscychresns.2018.08.013

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Meyer, Morawa, Nacak, Rösch, Forster and Ermm. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.